Pune, India, October 2019, MRFR Press Release/- Market Research Future has published a Half-Cooked Research Report on the Global Seborrheic Dermatitis Treatment Market.
According to MRFR analysis, Seborrheic Dermatitis Treatment Market is expected to register a CAGR of 10.5 % during the forecast period of 2019 to 2025 and was valued at USD 3.28 Billion by 2025.
Seborrheic dermatitis is a common skin disease that causes redness, scaly patches, and dandruff. It mainly affects the scalp, but it can also occur in other oily areas of the body, such as the upper chest, face, and back. The exact cause of seborrheic dermatitis is not yet fully understood. It is a long-term skin condition that requires constant treatment. Around 25% of people in the US are suffering from seborrheic dermatitis issues. According to a Japanese study, approximately 298 people were suffering from various seborrheic dermatitis in 2018. The growth of the global seborrheic dermatitis treatment market is impacted because of multiple factors including the increasing global geriatric population, rising prevalence of skin disorder, and subpar hygiene conditions. However, the high cost of treatment is expected to curb the growth of the global seborrheic dermatitis treatment market.
The global seborrheic dermatitis treatment market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of seborrheic dermatitis and rising per capita healthcare expenditure. The seborrheic dermatitis treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European seborrheic dermatitis treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The seborrheic dermatitis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of skin disorder and raising awareness about seborrheic dermatitis, the market in Asia-Pacific is expected to be the fastest-growing. The seborrheic dermatitis treatment market in the Middle East & Africa has been divided into the Middle East and Africa.
The global seborrheic dermatitis treatment market has been segmented based on treatment type, route of administration, and end user.
The market, based on treatment type, has been divided into antifungal products, corticosteroid lotions, and sulfur products. Around 1.5 million Americans are diagnosed with various seborrheic dermatitis every year. The corticosteroid lotions segment is predicted to be the fastest-growing due to the rising prevalence of the disorder in the pediatric population.
The global seborrheic dermatitis treatment market has been segmented, on the basis of route of administration, oral, and topical. The oral segment is expected to hold the majority share of the market. Around 25 million adults are diagnosed with chronic seborrheic dermatitis every year, and most of them treated with the help of oral drugs. The topical segment is expected to be the fastest-growing due to its increasing use globally. It was estimated that around 1.3 million people in the US were afflicted with seborrheic dermatitis in 2018.
The end-user segments of the market are hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is expected to hold the largest share of the market as these centers are the primary locations for patients receiving treatment and services.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/seborrheic-dermatitis-treatment-market-8499
Some of the key players in the Global Seborrheic Dermatitis Treatment Market are Sonoma Pharmaceuticals (US), Merck (US), Hikma Pharmaceuticals (UK), Allen and Hanburys (UK), GlaxoSmithKline (UK), Bausch Health (Canada), Valent Pharmaceutical (UK), and West-Ward Pharmaceutical Corp. (US).